Month: February 2024

•  Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 •  Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024 •  FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea •  FY 2023 total net revenue of $147.8 million, an increase of 5% year over year •  Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 •  Successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company’s recent...

Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress. The company’s strategic priorities for 2024 are focused on its pioneering RAS(ON) inhibitors:Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Studies in second line (2L) non-small cell lung cancer (NSCLC) and in 2L pancreatic ductal carcinoma (PDAC) are expected to begin in the second half of 2024. Expanding the reach of RMC-6236 monotherapy and/or combination regimens into earlier lines...

Q4 2023 revenue and adjusted EBITDA significantly exceeded guidance; Revenue growth accelerated to $84.6 million, up 14% over Q4 2022, delivered net income of $18.7 million or 22% margin, adjusted EBITDA of $38.9 million or 46% margin; Supply Path Optimization represented 45%+ of total activity in Q4 2023; Generated $81.1 million in cash from operations in 2023; Generated $52.8 million in free cash flow in 2023, a 38% increase over 2022 NO-HEADQUARTERS/REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “We ended 2023 on an incredibly high note, marking an inflection point in revenue growth as we accelerated...

Fourth quarter total revenue of $1,146.5 million, up 2.6% year over year as reported and 2.7% in constant currency; full fiscal year total revenue of $4,527.2 million, up 3.1% year over year as reported and 3.8% in constant currency Fourth quarter Enterprise revenue of $667.3 million, up 4.9% year over year; full fiscal year Enterprise revenue of $2,619.3 million, up 8.7% year over year Fourth quarter operating cash flow of $351.2 million, up 66.0% year over year; full fiscal year operating cash flow of $1,598.8 million, up 23.9% year over year; full fiscal year operating cash flow margin of 35.3% Authorization to repurchase up to $1.5 billion of Zoom’s Class A common stockSAN JOSE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a platform delivering limitless human connection, today announced...

Reports Full Year Revenues of $119.1 million, up 24% from Prior Year Net loss of $9.2 million, an improvement of $5.3 million versus prior year loss of $14.5 million Adjusted EBITDA (1) of $23.3 million, up 97% year over year Management Reiterates 2024 Revenue Guidance of $125.0 million-$129.0 million AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) — Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsRevenue of $26.3 million, down 10% year over year, excluding ERTC revenue up 15% from prior year Recurring revenue of $25.0 million, up 4% year over year, excluding ERTC recurring revenue up...

Fourth Quarter Revenue of $55.7 million Fourth Quarter Variable Marketing Margin of $20.7 million Full Year Revenue of $287.9 million Full Year Variable Marketing Margin of $100.3 millionCAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for EverQuote. We returned to our roots as a capital efficient digital insurance marketplace,” said Jayme Mendal, CEO of EverQuote. “We maintained positive Adjusted EBITDA for the year, improved our balance sheet, and our team managed effectively through historically low carrier demand.” “I am pleased with our outperformance in the fourth quarter, as we exceeded guidance across all three of our primary...

Results for the Quarter and Fiscal Year Ended December 31, 2023 and Other Recent Highlights:Net investment income per share for the quarter was $0.46, compared to $0.43 for the quarter ended September 30, 2023 Net asset value per share as of the end of the quarter was $15.41, compared to $15.28 as of September 30, 2023, an increase of 0.9% due to net investment income in excess of the dividend and a net gain on the portfolio New investment commitments made during the quarter totaled $175 million(1) Gross fundings, excluding revolver fundings(2), totaled $114 million for the quarter Net repayments, including revolvers(2), totaled $47 million for the quarter Net leverage(3) was 1.34x as of December 31, 2023 Declared a dividend of $0.38 per share for the quarter ending December 31, 2023(4) Completed Collateralized Loan Obligation (“CLO”)...

4Q’23 Marketplace Revenue further accelerated to 10% YoY, fastest pace in 10 quarters 4Q’23 Consolidated Net Loss of $(22.6) million, down 197% YoY; 4Q’23 Non-GAAP Consolidated Adjusted EBITDA of $61.2 million, up 120% YoY Repurchased $99.9 million worth of shares in 4Q’23 and a total of $204.1 million worth of shares in FY 2023 CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, buying, and selling new and used vehicles1, today announced financial results for the fourth quarter and year ended December 31, 2023. “We are extremely pleased with our performance, as our Marketplace business continued to accelerate in the fourth quarter, achieving the fastest pace of growth in nearly three years,” said Jason Trevisan, Chief Executive...

CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular...